Lan Z. Wang

发表

Structure-based design of 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinases 1 and 2.

M. Noble, J. Endicott, N. Curtin, 2003, Bioorganic & medicinal chemistry letters.

Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor

Jane A. Endicott, Thomas G. Davies, Nicola J. Curtin, 2002, Nature Structural Biology.

Transient treatment with CDK inhibitors eliminates proliferative potential even when their abilities to evoke apoptosis and DNA damage are blocked

N. Curtin, D. Newell, Lan Z. Wang, 2008, Cell cycle.

Supplemental Information Identi fi cation and Characterization of an Irreversible Inhibitor of CDK 2

Noble, J. Endicott, M. Geitmann, 2022 .

4-Alkoxy-2,6-diaminopyrimidine derivatives: inhibitors of cyclin dependent kinases 1 and 2.

L. Johnson, M. Noble, J. Endicott, 2003, Bioorganic & medicinal chemistry letters.

Synthesis and biological evaluation of 5-substituted O4-alkylpyrimidines as CDK2 inhibitors.

N. Curtin, I. Hardcastle, R. Griffin, 2010, Organic & biomolecular chemistry.

Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38α and BRD4.

M. Noble, J. Endicott, S. Cook, 2019, European journal of medicinal chemistry.

Effect of Cell Cycle Inhibition on Cisplatin-Induced Cytotoxicity

N. Curtin, R. Griffin, D. Newell, 2005, Journal of Pharmacology and Experimental Therapeutics.

Synthesis of sulfonamide-based kinase inhibitors from sulfonates by exploiting the abrogated SN2 reactivity of 2,2,2-trifluoroethoxysulfonates.

I. Hardcastle, R. Griffin, B. Golding, 2010, Organic & biomolecular chemistry.

Discriminative SKP2 Interactions with CDK-Cyclin Complexes Support a Cyclin A-Specific Role in p27KIP1 Degradation

M. Noble, J. Endicott, M. Pagano, 2020, bioRxiv.

Novel Poly(ADP-ribose) Polymerase-1 Inhibitor, AG14361, Restores Sensitivity to Temozolomide in Mismatch Repair-Deficient Cells

N. Curtin, B. Durkacz, D. Newell, 2004, Clinical Cancer Research.

Preclinical evaluation of a novel pyrimidopyrimidine for the prevention of nucleoside and nucleobase reversal of antifolate cytotoxicity

N. Curtin, R. Griffin, B. Golding, 2009, Molecular Cancer Therapeutics.

Parallel Optimization of Potency and Pharmacokinetics Leading to the Discovery of a Pyrrole Carboxamide ERK5 Kinase Domain Inhibitor

M. Noble, J. Endicott, S. Cook, 2022, Journal of medicinal chemistry.

Differences in the Conformational Energy Landscape of CDK1 and CDK2 Suggest a Mechanism for Achieving Selective CDK Inhibition

M. Noble, J. Endicott, Lan Z. Wang, 2019, Cell chemical biology.

Design, synthesis, and evaluation of 3,4-dihydro-2H-[1,4]diazepino[6,7,1-hi]indol-1-ones as inhibitors of poly(ADP-ribose) polymerase.

N. Curtin, R. Griffin, B. Golding, 2004, Journal of medicinal chemistry.

Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.

Robert Almassy, Kaye J Williams, N. Curtin, 2004, Journal of the National Cancer Institute.

Searching for cyclin-dependent kinase inhibitors using a new variant of the cope elimination.

M. Noble, J. Endicott, N. Curtin, 2006, Journal of the American Chemical Society.

Cyclin-Dependent Kinase (CDK) Inhibitors: Structure–Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines

M. Noble, J. Endicott, I. Hardcastle, 2016, Journal of medicinal chemistry.

Cyclin-Dependent Kinase (CDK) Inhibitors: Structure−Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substitued 2-Arylaminopurines

M. Noble, J. Endicott, I. Hardcastle, 2017 .

8-Substituted O(6)-cyclohexylmethylguanine CDK2 inhibitors: using structure-based inhibitor design to optimize an alternative binding mode.

D. Paterson, M. Noble, J. Endicott, 2014, Journal of medicinal chemistry.

N2-substituted O6-cyclohexylmethylguanine derivatives: potent inhibitors of cyclin-dependent kinases 1 and 2.

Yuzhu Chen, M. Noble, J. Endicott, 2004, Journal of medicinal chemistry.

Structure-based design of 2-arylamino-4-cyclohexylmethoxy-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinase 2.

M. Noble, J. Endicott, N. Curtin, 2007, Organic & biomolecular chemistry.

Identification and characterization of an irreversible inhibitor of CDK 2

M. Noble, J. Endicott, D. Staunton, 2017 .

Synthesis and Biological Evaluation of N2‐Substituted 2,4‐Diamino‐6‐cyclohexylmethoxy‐5‐nitrosopyrimidines and Related 5‐Cyano‐NNO‐azoxy Derivatives as Cyclin‐Dependent Kinase 2 (CDK2) Inhibitors

R. Fruttero, B. Golding, Lan Z. Wang, 2016, ChemMedChem.

Identification and Characterization of an Irreversible Inhibitor of CDK2

M. Noble, J. Endicott, D. Staunton, 2015, Chemistry & biology.

6-Cyclohexylmethoxy-5-(cyano-NNO-azoxy)pyrimidine-4-amine: a new scaffold endowed with potent CDK2 inhibitory activity.

P. Tosco, R. Fruttero, A. Gasco, 2013, European journal of medicinal chemistry.

Preclinical in vitro and in vivo evaluation of the potent and specific cyclin-dependent kinase 2 inhibitor NU6102 and a water soluble prodrug NU6301.

N. Curtin, I. Hardcastle, R. Griffin, 2011, European journal of cancer.

Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancer

I. Hardcastle, R. Griffin, B. Golding, 2016, British Journal of Cancer.

Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation

S. Cook, S. Wedge, D. Newell, 2016, Cell cycle.

Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial

N. Curtin, D. Newell, Lan Z. Wang, 2007, Molecular Cancer Therapeutics.

The CDK9 Tail Determines the Reaction Pathway of Positive Transcription Elongation Factor b

M. Noble, J. Endicott, S. Baumli, 2012, Structure.

Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: design, synthesis, and X-ray cocrystal structure.

N. Curtin, R. Griffin, B. Golding, 2002, Journal of medicinal chemistry.

An Alkynylpyrimidine-Based Covalent Inhibitor That Targets a Unique Cysteine in NF-κB-Inducing Kinase.

M. Noble, J. Endicott, M. Waring, 2021, Journal of medicinal chemistry.

Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies.

N. Curtin, B. Durkacz, D. Newell, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Anti-cancer chemosensitization in vitro and in vivo by a novel potent poly(ADP-ribose) polymerase (PARP1) inhibitor, TBI-361.

N. Curtin, S. Barton, R. Griffin, 2001 .

Differences in the Conformational Energy Landscape of CDK 1 andCDK 2 Suggest aMechanism for Achieving Selective CDK Inhibition Graphical

M. Noble, J. Endicott, Lan Z. Wang, 2018 .

Cyclin-Dependent Kinase (CDK) Inhibitors: Structure–Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines

M. Noble, J. Endicott, I. Hardcastle, 2016, Journal of medicinal chemistry.

Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines.

N. Curtin, B. Durkacz, D. Newell, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Novel Poly(ADP-ribose) Polymerase-1 Inhibitor, AG14361, Restores Sensitivity to Temozolomide in Mismatch Repair-Deficient Cells

N. Curtin, B. Durkacz, D. Newell, 2004, Clinical Cancer Research.